Generate Biomedicines (GENB) stock
GENB's Quality Score rose 1 point on Mon, Oct 5, to 0. Closed near the day's high.
Follow GENB's trial news. Pro members can get an alert when Generate Biomedicines files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
What's next for GENB, and how long its cash lasts
From Generate Biomedicines’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
$457M in cash
Dilution on the horizon
No shelf registration of its own or at-the-market program on file in the last three years.
Insiders
Director Frances Arnold sold 1,000 shares on Sep 1, under a planned sale. 5 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 24 daysINOInovio Pharmaceuticals
INOINO-3107
- In 35 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 47 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why GENB scores 0
Below AverageTrending down, 1 of 14 checks firingWhat the Quality Score means
- +1Chart checks 1 of 14 firing right now, one point each
- −1Volatility moves 7.2% a day with no profit or positive free cash flow over four quarters on file
What's next
Expected to report Thu Nov 5, before the open
After its last 2 reports it closed -7.7% on average, higher 0 of 2 times.
Sat Feb 27: One year since its IPOListed Feb 27, 2026 at $16.
What would turn GENB's score around: 4 things, for Pro members
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
GENB has 1 of 14 checks firing
One per group is shown here.
Also on the chart
- RSI 1438.2
- MACD (12, 26, 9)Below signal
- 50-day average$15.48
- ADX 1422.9
- Support$13.20
- Resistance$14.21
- Bollinger Bands (20, 2)Inside
- Volume0.9x
How GENB ranks in Biotech
GENB is #150 of 300 by Quality Score. The top three are shown with their scores, and more by name.
ONC8/1420
RGEN8/1420
CORT8/1418
FTHOpen for its score
FULCOpen for its score
GILDOpen for its score
GLUEOpen for its score
GENB1/140
When does GENB report earnings, and what happens after?
Expected to report Thu Nov 5, before the open (in 30 days). Not yet confirmed by the company.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 6, 2026Before open | Before open | -2.7% | -4.1% | +4.1% |
| May 7, 2026Before open | Before open | -3.4% | -11.2% | +6.0% |
About Generate Biomedicines
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
Pro members see every line of every stock's score.
- Real-time prices, no delay
- Every line of GENB's score, with the points and the reason
- All 14 checks on GENB and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on GENB
Straight Answers
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not to start. Tap any green button and you're in, free, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.